NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 12 Mar 2018 (#7)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

1. Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-CA-18-019) **Type:** ***R01***
(RFA-CA-18-020) ***R21***

Application Due Date: June 29, 2018, October 30, 2018Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.

The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Budget: NCI intends to commit $15 million in FY2019 to fund approximately 15-20 awards per round for two rounds. **R01 -** Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years. **R21 -** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Application budgets should reflect the actual needs of the proposed project. The total project period may not exceed 2 years.

2. Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-DA-19-005) **Type:** ***R61/R33***

Application Due Date: November 7, 2018 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA solicits applications proposing phased research projects, with transition milestones, to develop and rigorously test the effects of strategies to improve opioid treatment quality measures, both on changes in the measures themselves and on patient outcomes. The overall goal is to advance the field of clinical quality measurement and management in opioid use disorder treatment by generating research better aligning quality measurement with quality improvement.

Budget: NIDA intends to commit $2.5 million in FY 2019 to fund 5-6 awards. Direct costs will vary with the scope of the project. The R61 phase direct costs must not exceed $300,000 in any one year. The R33 phase direct costs must not exceed $500,000 in any one year The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 4 years for the R33 phase. Applications with a project period of less than 5 years are encouraged where feasible.

3. Basic and Translational Oral Health Research Related to HIV/AIDS (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-695) **Type:** ***R21***
(PA-18-699) ***R01***

Application Due Date: Standard dates and Standard AIDS dates. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages innovative basic and translational exploratory research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity.

Budget: R21 - The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years

4. Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-703) **Type:** ***R21***
(PAR-18-704) ***R01***

Application Due Date: July 11, 2018 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA), encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. NIEHS may support projects with a focus on innovative technology and method development

Budget: R21 - The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed 5 years.

5. Selective Cell and Network Vulnerability in Aging and Alzheimers Disease (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-706) **Type:** ***R01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this FOA is to define and characterize neural cell populations, neural circuits, and brain networks and regions that are vulnerable to brain aging and Alzheimer's disease (AD). Understanding mechanisms underlying selective vulnerability from cells to networks in AD is critical to fully define the disease process and to develop effective therapies.

Budget: NIA intends to commit $8 million in FY 2018 to fund 10-12 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

6. High Priority HIV/AIDS Research within the Mission of the NIDDK (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAS-18-698) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding.

Budget: NIDDK intends to fund an estimate of 6 to 9 awards, corresponding to a total of $3,500,000 per year, for fiscal year 2019 to 2021. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: ***comprehensive list of extramural grant and cooperative agreement activity codes***

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).